Regentis Biomaterials Ltd. (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product's planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC(R), which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion. The approval marks a critical step toward bringing this innovative therapy to patients suffering from cartilage damage.
The new manufacturing process eliminates the use of solvents, enhancing both occupational and environmental safety. By increasing yield and efficiency, Regentis is better positioned to scale production to meet anticipated demand in Europe and eventually in the United States, where no off-the-shelf treatment is currently available for the approximately 470,000 annual knee cartilage repair cases. The company's Gelrin platform technology, based on synchronized, degradable hydrogel implants, aims to regenerate damaged or diseased tissue including inflamed cartilage and bone.
For more details, the full press release is available at https://ibn.fm/Ths4h. Regentis Biomaterials continues to advance its regenerative medicine portfolio, focusing on orthopedic treatments that restore health and enhance quality of life. The company's lead product, GelrinC, is designed to be eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled, synchronous process. This regulatory approval brings Regentis closer to addressing a significant unmet medical need in cartilage repair.
